Showing results (961-970 of 1,344) with videos related to

Sort By:
Pageof 135
The Pharmacogenomics Journal|September 28, 2016
New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasisR Prieto-Pérez, G Solano-López, T Cabaleiro, et al.
The Pharmacogenomics Journal|September 28, 2016
IL17RA gene variants and anti-TNF response among psoriasis patientsA Batalla, E Coto, J Gómez, et al.
The Pharmacogenomics Journal|October 28, 2009
Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapyJi-Youn Han, Geon Kook Lee, Sun Young Yoo, et al.
The Pharmacogenomics Journal|November 11, 2009
Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancerF Toffalorio, E Giovannetti, T De Pas, et al.
The Pharmacogenomics Journal|November 18, 2009
ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychoticsY-R Liu, E-W Loh, T-H Lan, et al.
The Pharmacogenomics Journal|April 18, 2018
Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patientsCristina Pérez-Ramírez, Marisa Cañadas-Garre, Ahmed Alnatsha, et al.
The Pharmacogenomics Journal|July 12, 2017
Cytochrome P450 interactions are common and consequential in Massachusetts hospital dischargesT H McCoy, V M Castro, A Cagan, et al.
The Pharmacogenomics Journal|June 2, 2018
The in vitro functional analysis of single-nucleotide polymorphisms associated with growth hormone (GH) response in children with GH deficiencyChiara De Leonibus, Philip Murray, Terence Garner, et al.
The Pharmacogenomics Journal|June 22, 2018
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancerMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
The Pharmacogenomics Journal|February 25, 2015
Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapyL Paré-Brunet, A Sebio, J Salazar, et al.
Pageof 135